- Atezolizumab and bevacizumab in the treatment of hepatocellular carcinoma2020 | Faculty of Medicine in Pilsen
- Position of bevacizumab in the treatment of colorectal cancer2018 | First Faculty of Medicine
- Bevacizumab in the treatment of uterine cervix carcinoma2020 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Antiangiogenic treatment in breast cancer- case report, contemplation about position of bevacizumab2012 | Publication without faculty affiliation
- Efficiency of bevacizumab in treatment for relapsing ovarian cancer: case report2013 | First Faculty of Medicine
- Advanced hepatocellular carcinoma and successfully targeted the first-line treatment with atezolizumab and bevacizumab according to IMbrave150 trial2021 | Faculty of Medicine in Pilsen
- The importance of angiogenesis for the growth of ovarian cancer and the impact of bevacizumab2014 | Faculty of Medicine in Hradec Králové
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Lonsurf plus bevacizumab: A new standard in the third-line treatment of metastatic colorectal carcinoma2023 | Publication without faculty affiliation
- The use of bevacizumab (Avastin) in treating recurrent cervical cancer2017 | First Faculty of Medicine
- Therapy of metastatic non-squamous lung cancer with bevacizumab plus pemetrexed2016 | Faculty of Medicine in Pilsen
- Advanced breast carcinoma. Is it an indication for bevacizumab use?2015 | First Faculty of Medicine
- Urinary neopterin, serum retinol, alpha-tocopherol and homocysteine in breast cancer patients during treatment with bevacizumab and chemotherapy2010 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Bevacizumab in first-line therapy for metastatic colorectal cancer in combination with FOLFOX or XELOX2014 | First Faculty of Medicine
- First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma2008 | First Faculty of Medicine
- Comment to study: A randomized phase |III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild type (WT) KRAS metastatic colorectal cancer (mCRC) patients: German study AIO KRK-0306(FIRE-3)2013 | First Faculty of Medicine
- First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma2008 | Faculty of Medicine in Hradec Králové
- Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer - Czech Republic Model Adaptation2015 | Faculty of Medicine in Pilsen
- Current review of immunotherapy and anti-angiogenic lung cancer treatment2019 | Faculty of Medicine in Pilsen
- Indication Avastin in Ophthalmology2010 | Faculty of Medicine in Hradec Králové
- Bevacizumab for pediatric radiation necrosis2020 | Second Faculty of Medicine
- Follow-up of expensive pneumo-oncological treatment of advanced non-small cell lung cancer in the I. line of the TULUNG register in the Czech Republic2013 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence2020 | Second Faculty of Medicine
- Intravitreous Bevacizumab (Avastin) in neovascular age related macular degeneration (pilot study) +1Publication without faculty affiliation
- PARP inhibitor olaparib and anti-VEGF bevacizumab - targeted treatment and efforts to improve the outcome of patients with advanced tuboovarian cancer2020 | Faculty of Medicine in Pilsen
- Systemic therapy of cervical cancer - long-term effect of treatmentPublication without faculty affiliation
- Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis2014 | First Faculty of Medicine
- Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab2014 | Third Faculty of Medicine